News
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 ...
Hosted on MSN1mon
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL marketachieving key milestones, advancing ZYNLONTA, and strengthening the balance sheet. The company completed enrollment in the pivotal Phase 3 LOTIS-5 trial and presented data from the initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback